Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 861-873

  Majhail, Navneet S ^a   Brazauskas, Ruta ^b   Hassebroek, Anna ^a   Bredeson, Christopher N ^c   Hahn, Theresa ^d   Hale, Gregory A ^e   Horowitz, Mary M ^b   Lazarus, Hillard M ^f   Maziarz, Richard T ^g   Wood, William A ^h   Parsons, Susan K ⁱ   Joffe, Steven ^j   Rizzo, J Douglas ^b   Lee, Stephanie J ^k   Hayes Lattin, Brandon M ^g  

^a NATIONAL MARROW DONOR PROGRAM   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

Acute myeloid leukemia; Adolescent and young adults; Allogeneic; Hematopoietic cell transplantation; Survival

Indexed keywords

CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK REDUCTION; SIBLING; UNRELATED DONORS;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84860840686     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.031     Document Type: Article

References (18)

1. Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 2005, 35:182-217.
2. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer 2006, Adolescent and Young Adult Oncology Progress Review Group, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and the LiveStrong Young Adult Alliance. NIH Publication No. 06-6067, Bethesda, MD, Available at:. http://planning.cancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf.
3. Bleyer W.A. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 2002, 38:1-10.
4. Zebrack B., Mathews-Bradshaw B., Siegel S. Quality cancer care for adolescents and young adults: a position statement. J Clin Oncol 2010, 28:4862-4867.
5. Albritton K., Bleyer W.A. The management of cancer in the older adolescent. Eur J Cancer 2003, 39:2584-2599.
6. Wood W.A., Lee S.J. Malignant hematologic diseases in adolescents and young adults. Blood 2011, 117:5803-5815.
7. Horan J.T., Logan B.R., Agovi-Johnson M.A., et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?. J Clin Oncol 2011, 29:805-813.
8. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
9. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006, 12:876-884.
10. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides Available at:, accessed 05/01/2011. http://www.cibmtr.org.
11. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
12. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009, 15:367-369.
13. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
14. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985, 53:457-481.
16. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
17. Mattano L., Nachman J., Ross J., Stock W. Leukemias. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. NIH Pub. No. 06-5767 2006, National Cancer Institute, Bethesda, MD, Available at:. http://seer.cancer.gov/publications/aya/aya_mono_complete.pdf, A. Bleyer, M. O'Leary, R. Barr, L.A.G. Ries (Eds.).
18. Bishop M.R., Alyea E.P., Cairo M.S., et al. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011, 17:443-454.